SPIRIT III JAPAN Versus SPIRIT III USA: A Comparative Intravascular Ultrasound Analysis of the Everolimus-Eluting Stent

Shimohama, Takao; Ako, Junya; Yamasaki, Masao; Otake, Hiromasa; Tsujino, Ichizo; Hasegawa, Takao; Nakatani, Daisaku; Sakurai, Ryota; Chang, Hyeonsoo; Kusano, Hajime; Waseda, Katsuhisa; Honda, Yasuhiro; Stone, Gregg W.; Saïto, Shigeru; Fitzgerald, Peter J.; Sudhir, Krishnankutty

doi:10.1016/j.amjcard.2010.02.008

Cited by 31 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the previous IVUS study, stents from the "limus" family, such as sirolimus, zotarolimus and everolimus, did not show significant differences in vessel and peri-stent plaque. 10-12, 18 These findings were confirmed in the ZoMaxx stent, which is a new zotarolimuseluting stent with a PC coating. In contrast, previous studies using paclitaxel-eluting stents showed a significant increase in vessel and peri-stent plaque regardless of elution time, paclitaxel dose or polymer type.…”

Section: Peri-stent Vessel Responsesupporting

confidence: 56%

Comparison of Vascular Response to Zotarolimus-Eluting Stent vs Paclitaxel-Eluting Stent Implantation - Pooled IVUS Results From the ZoMaxx I and II Trials -

Waseda

Hasegawa

Ako

et al. 2010

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Peri-stent Vessel Responsesupporting

confidence: 56%

Comparison of Vascular Response to Zotarolimus-Eluting Stent vs Paclitaxel-Eluting Stent Implantation - Pooled IVUS Results From the ZoMaxx I and II Trials -

Waseda

Hasegawa

Ako

et al. 2010

Circ J

Self Cite

View full text Add to dashboard Cite

“…31 Volume obstruction was also lower with the new novolimus-eluting stent (6.0%). 32 The neointimal volume index of 1.58 mm 3 /mm was also significantly lower than that found in the BMS group, but significantly higher than that of the EES group, and again higher than the historical indices reported for EES (0.2-0.4 mm 3 /mm), 30 zotarolimus-eluting stents (0.2- Data given as mean ± SD. *Data given as '% (n)'.…”

Section: Discussionmentioning

confidence: 94%

First-in-Man Study of Simvastatin-Eluting Stent in De Novo Coronary Lesions

Zago

Matte

Reginato

et al. 2012

Circ J

View full text Add to dashboard Cite

“…Newer generation stents also seem to be highly effective. 55 Obviously, in this setting, the effects on the endothelium are greater because of the high local drug concentrations.…”

Section: Endothelium Atherosclerosis and Heart Transplantationmentioning

confidence: 99%

Long-term outcome of everolimus treatment in transplant patients

Salvadori

Bertoni²

2011

TRRM

View full text Add to dashboard Cite

Abstract:The authors review the use of everolimus in long-term studies both in renal and heart transplantation. The pharmacokinetic and pharmacodynamic differences between everolimus and its parent drug, sirolimus are discussed. The improved pharmacokinetic, in particular the improved bioavailability, the reduced half-time and the reduced binding to plasma protein makes everolimus the first choice among the proliferation signal inhibitors. Everolimus is given in almost all studies in association with cyclosporine, but fixed doses of this drug can cause nephrotoxicity. The first studies used everolimus and CsA in fixed doses, but later studies with reduced CsA doses revealed which revealed improved outcomes. Finally, therapeutic drug monitoring became the better choice for both drugs. Recently very high everolimus exposure allowed the use of very low CsA exposure with improvement of the worse side effects linked to the CsA standard dose. The Zeus study revealed a complete and safe CsA withdrawal, thanks to everolimus and mycophenolic acid. In heart transplantation, everolimus resulted in improved outcomes with respect to antiproliferative drugs such as mycophenolic acid and azathioprine. Along with antirejection properties, everolimus provided evidence for antiproliferative effects on several cells. This resulted in fewer viral infections (mainly CMV), anti-atherosclerotic properties (mainly important in heart transplantation, and antineoplastic effect. The latter activity resulted in lower cancer incidence in transplant patients treated by everolimus. An important piece of evidence for this activity is documented by the use of everolimus in the treatment of some cancers, including renal cancer, neuroendocrine cancers and hepatocellular cancers, also outside the field of transplantation.

show abstract

SPIRIT III JAPAN Versus SPIRIT III USA: A Comparative Intravascular Ultrasound Analysis of the Everolimus-Eluting Stent

Cited by 31 publications

References 16 publications

Comparison of Vascular Response to Zotarolimus-Eluting Stent vs Paclitaxel-Eluting Stent Implantation - Pooled IVUS Results From the ZoMaxx I and II Trials -

Comparison of Vascular Response to Zotarolimus-Eluting Stent vs Paclitaxel-Eluting Stent Implantation - Pooled IVUS Results From the ZoMaxx I and II Trials -

First-in-Man Study of Simvastatin-Eluting Stent in De Novo Coronary Lesions

Long-term outcome of everolimus treatment in transplant patients

Contact Info

Product

Resources

About